Skip to main content
MACROGENICS INC logo

MACROGENICS INC — Investor Relations & Filings

Ticker · MGNX ISIN · US5560991094 LEI · 5493001KJQUA83L8MH79 US Manufacturing
Open in API
Filings indexed 894 across all filing types
Latest filing 2016-05-17 Director's Dealing
Country US United States of America
Listing US MGNX

About MACROGENICS INC

https://www.macrogenics.com/

MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative antibody-based therapeutics for the treatment of cancer. The company utilizes its proprietary antibody engineering platforms, including the DART (Dual-Affinity Re-Targeting) and TRIDENT technologies, to create novel product candidates. Its pipeline consists of investigational treatments such as monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific antibodies. MacroGenics maintains fully-integrated capabilities, from research and discovery through to GMP (Good Manufacturing Practice) manufacturing, to advance its portfolio of potential medicines for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2016-05-17 English
FORM 4
Director's Dealing
2016-05-13 English
FORM 10-Q
Interim / Quarterly Report Q1 2016
2016-05-04 English
Earnings Release 2016
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically states that the company announced financial and operating results for the period ended March 31, 2016, and that the full text of the press release is attached as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references a press release. The length of the document is 2878 characters, which is relatively short and consistent with an announcement rather than a full earnings release. According to the classification rules, initial announcements of quarterly or periodical financial results (key highlights only) are classified as Earnings Release (ER). Since this is a Form 8-K announcing financial results and attaching a press release, it fits best under Earnings Release (ER).
2016-05-04 English
FORM 4
Director's Dealing
2016-04-29 English
DEF 14A
Proxy Solicitation & Information Statement
2016-04-07 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.